Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

279
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
279
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

657
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
657
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation01:24

One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation

1.3K
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
1.3K
Determination of Renal Drug Clearance: Graphical and Midpoint Methods01:07

Determination of Renal Drug Clearance: Graphical and Midpoint Methods

442
Renal clearance, a crucial parameter in pharmacokinetics, can be determined using two different methods: the graphical method and the midpoint method. These methods provide insights into the rate of drug excretion by the kidneys and aid in assessing renal function.
The graphical method involves plotting the rate of drug excretion in urine against the plasma drug concentration. By analyzing the graph, the clearance can be calculated and obtained. Drugs rapidly excreted by the kidneys exhibit a...
442
Mechanistic Models: Compartment Models in Algorithms for Numerical Problem Solving01:29

Mechanistic Models: Compartment Models in Algorithms for Numerical Problem Solving

370
Mechanistic models play a crucial role in algorithms for numerical problem-solving, particularly in nonlinear mixed effects modeling (NMEM). These models aim to minimize specific objective functions by evaluating various parameter estimates, leading to the development of systematic algorithms. In some cases, linearization techniques approximate the model using linear equations.
In individual population analyses, different algorithms are employed, such as Cauchy's method, which uses a...
370
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

658
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
658

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
Same author

An Ether-Containing Hafnium-Diethylene Glycol Dry Resist Prepared by Molecular Layer Deposition for Mild-Acid Development.

Nanomaterials (Basel, Switzerland)·2026
Same author

Perturbing glycosylphosphatidylinositol (GPI)-anchor biosynthesis alters cell wall architecture and modulates fungal morphology.

bioRxiv : the preprint server for biology·2026
Same author

Mycoelectronics: Bioprinted living fungal bioelectronics for artificial sensation.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

CXCL8 Enhances Malignancy of GBM via TNFα-NFκB Mediated Suppression of Ferroptosis.

Applied biochemistry and biotechnology·2026
Same author

Tuning *OH Oxidativity via a Cu-Co(OH)<sub>2</sub> Cocatalyst on a Hematite Photoanode for Selective Cyclohexanone Oxidation.

Journal of the American Chemical Society·2026
Same journal

Different Clinical Questions Need Different Estimands.

Therapeutic innovation & regulatory science·2026
Same journal

Medicinal Chemistry Perspectives on Drug Repurposing: Innovative Approaches and Therapeutic Breakthrough.

Therapeutic innovation & regulatory science·2026
Same journal

Understanding the Added Value of Action Limits for QTL Monitoring.

Therapeutic innovation & regulatory science·2026
Same journal

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Therapeutic innovation & regulatory science·2026
Same journal

Validation of the Ontario Protocol Assessment Level (OPAL) Tool for Assessing Clinical Trial Complexity and Supporting Workforce Planning in the Italian Clinical Research Context.

Therapeutic innovation & regulatory science·2026
Same journal

The Effect of Covariate Adjustment for Cox Regression in Cardiovascular Outcome Trials.

Therapeutic innovation & regulatory science·2026
関連記事をすべて見る

関連する実験動画

Updated: Feb 26, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

874

eGFRスロープ推定および様々な推定方法間での比較分析のための推定値フレームワーク開発

Tuo Wang1, Yu Du2

  • 1Global Statistical Sciences, Eli Lilly and Company, Indianapolis, Indiana, USA. tuo.wang@lilly.com.

Therapeutic innovation & regulatory science
|February 25, 2026
PubMed
まとめ
この要約は機械生成です。

慢性腎臓病(CKD)臨床試験の結果を改善するために、推定糸球体濾過量(eGFR)スロープを推定するための標準化されたフレームワークが提案されています。このアプローチは、CKD治療法の開発における信頼性と比較可能性を高めます。

キーワード:
eGFRスロープ推定値慢性腎臓病混合効果モデル代理エンドポイント

さらに関連する動画

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.8K

関連する実験動画

Last Updated: Feb 26, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

874
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.8K

科学分野:

  • 腎臓病学
  • 臨床試験
  • 生物統計学

背景:

  • 慢性腎臓病(CKD)は世界的な健康問題であり、末期腎臓病(ESKD)への進行は死亡率の増加につながります。
  • CKD試験における従来の腎臓複合エンドポイントには、長い追跡期間が必要です。
  • 推定糸球体濾過量(eGFR)スロープは、腎機能低下の有用な代理エンドポイントですが、標準化された推定方法が不足しています。

研究 の 目的:

  • CKD無作為化比較試験(RCT)におけるeGFRスロープベースの分析のための新しい推定値フレームワークを提案すること。
  • 推定値の定義を明確にし、CKD試験間での結果の比較可能性を向上させること。
  • さまざまなシナリオにおけるeGFRスロープのさまざまな推定技術のパフォーマンスを評価すること。

主な方法:

  • CKD RCTにおけるeGFRスロープのための調整された推定値フレームワークの開発。
  • 推定技術を評価するためのシミュレーション研究の実施。
  • さまざまなシナリオにおけるeGFRスロープのさまざまな推定技術のパフォーマンスを評価すること。

主要な成果:

  • 提案されたフレームワークは、eGFRスロープ推定値の明確な定義を提供します。
  • 評価により、特に競合イベント率が低いシナリオに適した推定アプローチが特定されました。
  • 本研究は、推定方法と特定の試験目標を整合させることの重要性を強調しています。

結論:

  • 標準化された推定値フレームワークは、CKD試験における信頼性が高く解釈可能なeGFRスロープ分析に不可欠です。
  • この作業は、CKD試験結果の一貫性を向上させることにより、治療法の開発を前進させます。
  • 本研究の結果は、慢性腎臓病の管理におけるより良い臨床的意思決定を支持します。